Business & Finance
Ambu names Juan-José Gonzalez as new CEO
13 May 2019 -

Ambu A/S (CPH:AMBUB), a developer, producer and marketer of life-saving equipment, announced on Friday the appointment of Juan-José Gonzalez as the new CEO, effective 15 May 2019.

The company said Gonzales replaces Lars Marcher, who has resigned from his position.

Gonzalez, who has held a number of senior positions in the US healthcare group Johnson & Johnson for the past 12 years, most recently was president for the activities of the subsidiary DePuy Synthes in the US.

Prior to joining Johnson & Johnson in 2007, Gonzalez was a commercial director of the pharmaceutical company Pfizer, responsible for Europe, Africa and the Middle East. Before that, he was employed by the global consulting firm McKinsey & Company for five years.

Ambu clarified that the replacement of the CEO does not change the announced financial expectations for 2018/19, or the financial targets for 2020 as outlined in the Big Five strategy, except for the one-off costs,

In relation to Marcher's resignation, there will be one-off costs of approximately DKK 38m, which for accounting purposes will be recognised in the income statement as Special items. These costs relate, to among other things, salary during the period of notice and the costs of the remaining value of already granted share options calculated according to the Black Scholes formula. These Black Scholes costs amounts to DKK16m, which so far has been distributed over the allocation period of the share options, but will now be fully charged to the income statement in Q3 of the financial year 2018/19 as a direct consequence of Marcher's resignation.

Ambu provides professional diagnostic, life supporting and training equipment. Ambu's products are used for respiratory support and cardiopulmonary resuscitation, immobilisation and protection against infections. The company sells to hospitals, rescuers, armed forces and industries.